Skip to main content
Top
Published in: European Journal of Nutrition 7/2019

01-10-2019 | Original Contribution

Effects of products designed to modulate the gut microbiota on hyperlipidaemia

Authors: Xilong Deng, Jie Ma, Meiting Song, Ye Jin, Cheng Ji, Weihong Ge, Changrun Guo

Published in: European Journal of Nutrition | Issue 7/2019

Login to get access

Abstract

Purpose

Fatalities due to heart and cerebrovascular diseases caused by uncontrolled hyperlipidaemia increase every year; on the other hand, lipid-lowering drugs are known to cause side effects. The gut microbiota has been thoroughly investigated by researchers and consumers, because they have unique functional properties and littler side effects. However, the effects of the gut microbiota remain controversial. We conducted a meta-analysis to assess the effects of products designed to modulate the gut microbiota on various hyperlipidaemias.

Methods

We systematically searched PubMed, Embase, Cochrane Library (Central), and Web of Science for randomized controlled trials (published before June 2017, and those only in English) to compare treatment (products designed to modulate the gut microbiota) versus placebo. Our main endpoints were total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in serum. We assessed pooled data using a fixed effects model.

Results

Of 1337 identified studies, 21 were eligible and included in our analysis (n = 1436 participants). The combined estimate of effect size for the impact of products designed to modulate the gut microbiota on serum TC (WMD − 11.07 mg/dL, 95% CI − 13.72 to − 8.43, p < 0.001), LDL-C (WMD − 10.96 mg/dL, 95% CI − 13.37 to − 8.56, p < 0.001), and HDL-C (WMD 0.72 mg/dL, 95% CI 0.06–1.38, p = 0.032) were statistically significant, while no significant effect was found on TG concentrations (WMD − 0.56 mg/dL, 95% CI − 5.59 to 4.47, p = 0.828). Subgroup analysis showed parallel trials, probiotics, and long-term intervention had better effects on lowering blood lipid levels.

Conclusion

Products designed to modulate the gut microbiota results in changes of the plasma lipid concentrations and these changes may protect against cardiovascular disease.
Appendix
Available only for authorised users
Literature
4.
go back to reference Obesity CRi (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143–3421CrossRef Obesity CRi (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143–3421CrossRef
9.
go back to reference Flint HJ, Scott KP, Louis P, Duncan SH (2012) The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 9(10):577–589CrossRef Flint HJ, Scott KP, Louis P, Duncan SH (2012) The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 9(10):577–589CrossRef
16.
go back to reference De Roos NM, Scheuten G, Katan MB (1999) Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr 53(4):277–280CrossRef De Roos NM, Scheuten G, Katan MB (1999) Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr 53(4):277–280CrossRef
20.
go back to reference Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A (2011) Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 94(7):3288–3294. https://doi.org/10.3168/jds.2010-4128 CrossRefPubMed Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A (2011) Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 94(7):3288–3294. https://​doi.​org/​10.​3168/​jds.​2010-4128 CrossRefPubMed
23.
go back to reference Agerholm-Larsen LBM, Grunwald GK, Astrup A (2000) The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr 54:856–860CrossRef Agerholm-Larsen LBM, Grunwald GK, Astrup A (2000) The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr 54:856–860CrossRef
29.
go back to reference Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRef Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463CrossRef
32.
go back to reference Bertolami MC, Faludi AA, Batlouni M (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr 53(2):97–101CrossRef Bertolami MC, Faludi AA, Batlouni M (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr 53(2):97–101CrossRef
34.
go back to reference St-Onge MP, Farnworth ER, Savard T, Chabot D, Mafu A, Jones PJ (2002) Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial. BMC Complement Altern Med 2:1–7CrossRef St-Onge MP, Farnworth ER, Savard T, Chabot D, Mafu A, Jones PJ (2002) Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial. BMC Complement Altern Med 2:1–7CrossRef
35.
go back to reference Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A (2003) Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 86(7):2452–2461CrossRef Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, Iwatsuki K, Kokubo S, Hosono A (2003) Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 86(7):2452–2461CrossRef
37.
go back to reference Hlivak P, Odraska J, Ferencik M, Ebringer L, Jahnova E, Mikes Z (2005) One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratislavské lekárske listy 106(2):67–72PubMed Hlivak P, Odraska J, Ferencik M, Ebringer L, Jahnova E, Mikes Z (2005) One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratislavské lekárske listy 106(2):67–72PubMed
38.
go back to reference Hatakka K, Mutanen M, Holma R, Saxelin M, Korpela R (2008) Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 27(4):441–447CrossRef Hatakka K, Mutanen M, Holma R, Saxelin M, Korpela R (2008) Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 27(4):441–447CrossRef
39.
41.
go back to reference Berthold HK, Schulte DM, Lapointe JF, Lemieux P, Krone W, Gouni-Berthold I (2011) The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial1. J Dairy Sci 94(2):589–601. https://doi.org/10.3168/jds.2010-3115 CrossRefPubMed Berthold HK, Schulte DM, Lapointe JF, Lemieux P, Krone W, Gouni-Berthold I (2011) The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial1. J Dairy Sci 94(2):589–601. https://​doi.​org/​10.​3168/​jds.​2010-3115 CrossRefPubMed
45.
go back to reference Ahn HY, Kim M, Ahn YT, Sim JH, Choi ID, Lee SH, Lee JH (2015) The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects. Nutr Metabol Cardiovasc Dis 25(8):724–733. https://doi.org/10.1016/j.numecd.2015.05.002 CrossRef Ahn HY, Kim M, Ahn YT, Sim JH, Choi ID, Lee SH, Lee JH (2015) The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects. Nutr Metabol Cardiovasc Dis 25(8):724–733. https://​doi.​org/​10.​1016/​j.​numecd.​2015.​05.​002 CrossRef
47.
go back to reference Cavallini DC, Manzoni MS, Bedani R, Roselino MN, Celiberto LS, Vendramini RC, de Valdez G, Abdalla DS, Pinto RA, Rosetto D, Valentini SR, Rossi EA (2016) Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: a randomized controlled trial. Nutrients 8(1):52–70. https://doi.org/10.3390/nu8010052 CrossRef Cavallini DC, Manzoni MS, Bedani R, Roselino MN, Celiberto LS, Vendramini RC, de Valdez G, Abdalla DS, Pinto RA, Rosetto D, Valentini SR, Rossi EA (2016) Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: a randomized controlled trial. Nutrients 8(1):52–70. https://​doi.​org/​10.​3390/​nu8010052 CrossRef
49.
go back to reference Tan S, Zhao A, Zheng Y, Wang P, Zhang Y (2017) Effects of Lactobacillus paracasei N1115 on intestinal microbiota and serum lipid of dyslipidemias. FASEB J 31 (1 Supplement):45–46 Tan S, Zhao A, Zheng Y, Wang P, Zhang Y (2017) Effects of Lactobacillus paracasei N1115 on intestinal microbiota and serum lipid of dyslipidemias. FASEB J 31 (1 Supplement):45–46
50.
go back to reference Gilliland SE, Nelson CR, Maxwell C (1985) Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 49(2):377–381PubMedPubMedCentral Gilliland SE, Nelson CR, Maxwell C (1985) Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 49(2):377–381PubMedPubMedCentral
51.
go back to reference Pereira DI, Gibson GR (2002) Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 68(9):4689–4693CrossRef Pereira DI, Gibson GR (2002) Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 68(9):4689–4693CrossRef
53.
go back to reference Tahri K, Grill JP, Schneider F (1997) Involvement of trihydroxyconjugated bile salts in cholesterol assimilation by bifidobacteria. Curr Microbiol 34(2):79–84CrossRef Tahri K, Grill JP, Schneider F (1997) Involvement of trihydroxyconjugated bile salts in cholesterol assimilation by bifidobacteria. Curr Microbiol 34(2):79–84CrossRef
54.
go back to reference Zhao JR, Yang H (2005) Progress in the effect of probiotics on cholesterol and its mechanism. Wei sheng wu xue bao = Acta microbiologica Sinica 45(2):315–319PubMed Zhao JR, Yang H (2005) Progress in the effect of probiotics on cholesterol and its mechanism. Wei sheng wu xue bao = Acta microbiologica Sinica 45(2):315–319PubMed
57.
go back to reference Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101–105CrossRef Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101–105CrossRef
Metadata
Title
Effects of products designed to modulate the gut microbiota on hyperlipidaemia
Authors
Xilong Deng
Jie Ma
Meiting Song
Ye Jin
Cheng Ji
Weihong Ge
Changrun Guo
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 7/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-018-1821-z

Other articles of this Issue 7/2019

European Journal of Nutrition 7/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.